• Mashup Score: 1
    Addition of Neoadjuvant Talimogene Laherparepvec to Surgery in Advanced Melanoma: 5-Year Follow-up - The ASCO Post - 8 month(s) ago

    As reported in a research letter in JAMA Oncology by Reinhard Dummer, MD, and colleagues, the final, 5-year analysis of a phase II trial showed continued improvement in outcomes with the addition of neoadjuvant talimogene laherparepvec (T-VEC) to surgery in patients with advanced melanoma. In the open-label trial, 150 patients from sites in nine countries were randomly assigned beginning in February 2015 to receive six doses of neoadjuvant intralesional T-VEC followed by surgery (n = 76) or immediate

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Addition of Neoadjuvant Talimogene Laherparepvec to Surgery in Advanced Melanoma: 5-Year Follow-up https://t.co/wmEelt30dE #melsm #melanoma #oncology #skcsm

  • Mashup Score: 0
    The efficacy of immunotherapy across sarcoma subtypes - 8 month(s) ago

    Javier Martin Broto, MD, PhD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, explains how there are many subtypes of sarcoma, which respond differently to select treatments. In ultra-rare sarcomas, unique approaches have been developed over the last decade. Immunotherapy has been shown to be vital, with anti-PD1 therapy in alveolar soft part sarcoma (ASPS). CSF1 inhibitors, such as pexidartinib, are an example of tyrosine-kinase inhibitors (TKIs) for rare sarcomas. In common sarcoma types, new combinations and targets are still being investigated. Recently, cabozantinib has be trialed in different sarcoma types. It is important to remember that different sarcoma subtypes will show different levels of response to novel TKIs. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights

    Source: www.vjoncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥@BrotoJavier of @Hospital_FJD discusses diverse sarcoma subtypes and tailored treatments. Immunotherapy's role in rare sarcomas and evolving TKI combinations for common types are key focus areas: ➡️https://t.co/PMeK3bchBT⬅️ #ASCO23 #skcsm

  • Mashup Score: 0
    Cancer Vaccine IFx-Hu2.0 Confers Immune Priming Effect in Previously Treated MCC and CSCC - 9 month(s) ago

    The novel personalized cancer vaccine IFx-Hu2.0 was found to be safe and well tolerated with weekly dosing in patients with checkpoint inhibitor–resistant cutaneous squamous cell carcinoma and Merkel cell carcinoma, according to data from an ongoing phase 1b trial.

    Source: www.onclive.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      In an exploratory post-hoc analysis, 71% of patients given standard ICI therapy after IFx-Hu2.0 injection experienced a durable objective response despite having progressive disease prior to enrollment. @JCO_ASCO #ASCO23 #skcsm https://t.co/2zbHgZrrNv https://t.co/QDUKm8AFrs

  • Mashup Score: 2
    The personalization of neoadjuvant immunotherapy in stage III melanoma - 9 month(s) ago

    Minke Lucas, MD, from The Netherlands Cancer Institute, delves into the significance of predictive biomarkers in determining neoadjuvant regimens for melanoma patients. She emphasizes the crucial role of the pathological response rate in guiding treatment decisions after neoadjuvant therapy. Patients with a major pathological response might not require further adjuvant treatment and could benefit from deescalated surgery. In contrast, those with a partial or non-response might need more extensive surgery and potential adjuvant therapy due to higher recurrence risks. This tailored approach aims to personalize neoadjuvant immunotherapy strategies, optimizing surgical procedures and post-treatment care based on individual response profiles. This interview occurred at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights ar

    Source: www.vjoncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥Minke Lucas, MD, from @NKI_nl explores the role of predictive biomarkers in melanoma neoadjuvant regimens. Tailored treatments based on pathological response could optimize outcomes and reduce risks: ➡️https://t.co/msNjGl67cB⬅️ #ASCO23 #Skcsm #MelSM

  • Mashup Score: 0
    Skin Cancer Screenings and Melanoma Outcomes Among Racial and Ethnic Minority Patients - The ASCO Post - 9 month(s) ago

    Although melanoma—the leading cause of skin cancer mortality—is most common among White patients, the survival outcomes of melanoma are often poorer among patients with darker skin tones. Although individuals often think of melanoma as a type of cancer caused by sun exposure, certain types of melanoma can arise on the palms of the hand, soles of the feet, and places that are always covered by clothes—and they tend to be more common in patients with darker skin tones. “In this study, we asked whether

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Skin Cancer Screenings and Melanoma Outcomes Among Racial and Ethnic Minority Patients https://t.co/OsZbLsNevV #skcsm #melsm #melanoma #screening #healthequity

Load More